1] More than half (55 percent) of cardiologists and pulmonologists surveyed wish that general practitioners would better understand the specific signs and symptoms of CTEPH
and pulmonary arterial hypertension (PAH), so that they can see patients sooner.
We are very pleased to see Bayer's commitment to CTEPH
patients and their work to raise awareness about the disease," said Rino Aldrighetti, president and CEO of the Pulmonary Hypertension Association, Silver Spring, Md.
Bayer and PHA celebrate PH Awareness month in November, and will observe CTEPH
Awareness Day on November 18 annually moving forward.
Every patient diagnosed with CTEPH
should be evaluated by an expert CTEPH
team, including a CTEPH
physician and PEA surgeons, to assess their candidacy for PEA surgery.
PAH and CTEPH
are two rare and life-threatening forms of pulmonary hypertension characterized by significantly increased pressure in the pulmonary arteries.
It is the first and only FDA-approved drug therapy for persistent/recurrent CTEPH
after surgical treatment or inoperable CTEPH
To date, there is no pharmacological treatment available for CTEPH
In the first interim analysis in CHEST-2, riociguat was shown to be well tolerated with a good long-term safety profile in patients with CTEPH
Riociguat is the first drug to demonstrate clinical efficacy in a placebo controlled phase III trial in inoperable CTEPH
If approved by the FDA, riociguat will be the first treatment for inoperable CTEPH
or persistent/recurrent CTEPH
after surgery and a new treatment for PAH
Riociguat (BAY 63-2521), discovered and developed at the Bayer research laboratories, is an investigational oral soluble guanylate cyclase (sGC) stimulator that is being studied in CTEPH
and PAH, as well as other forms of pulmonary hypertension.
Food and Drug Administration (FDA) seeking approval for riociguat, an investigational compound for the treatment of pulmonary arterial hypertension (PAH) and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH
) after surgical treatment or inoperable CTEPH